Cargando…
Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
OBJECTIVE: The clinical efficacy and safety profile of trastuzumab deruxtecan (T-DXd) have been demonstrated in previously treated patients with human epidermal growth factor receptor 2 (HER2)-low advanced breast cancer (BC). It is, however, necessary to evaluate the value of T-DXd considering both...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449172/ https://www.ncbi.nlm.nih.gov/pubmed/37616309 http://dx.doi.org/10.1371/journal.pone.0290507 |